- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: $1 Alternative to Pricey Daraprim
What we're reading, December 1, 2015: $1 alternative to Daraprim being made available; over-the-counter medications are convenient and affordable but have their own dangers; and an analysis looks at the reasons why prescription drugs are so much more expensive in the US.
Express Scripts Will Sell $1 Daraprim Alternative
Following Turing Pharmaceuticals’ controversial decision to increase the price of the 62-year-old Daraprim to $750 a pill from $13.50 a pill, Express Scripts and Imprimis Pharmaceuticals will partner to increase access to a low-cost alternative of the drug. Daraprim is used to treat toxoplasmosis and the price increase puts it out of reach for people with HIV, pregnant women, and others with weakened immune systems. The compounded alternative will only cost $1 per capsule.
The Dangers of Over-the-Counter Medications
Over-the-counter medications used commonly to treat a variety of ailments are convenient and affordable, but are often used inappropriately. The New York Times reported that one-fifth of American adults admit to taking more than the recommended dose and using over-the-counter medications more frequently than they should. In addition, few consult a doctor or pharmacists first.
Behind the Higher Cost of Prescription Drugs in America
Although the cost of living in Norway is higher than the US, the price of prescription drugs is far higher in America, according to an analysis from The Wall Street Journal. Comparing drug prices paid for by Medicare Part B with those paid by Norway’s taxpayer-funded health system, the analysis revealed that 93% of 40 top branded drugs were more expensive in the US. The Journal found similar results when comparing the US to England and Canada’s Ontario province.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
